Effect of Tolfenamic Acid on Canine Cancer Cell Proliferation, Specificity Protein (Sp) Transcription Factors, and Sp-Regulated Proteins in Canine Osteosarcoma, Mammary Carcinoma, and Melanoma Cells

Journal of Veterinary Internal Medicine

Volumn 26, Issue 4, 2012, Pages 977-986

  Wilson, H ^a   Chadalapaka, G ^a   Jutooru, I ^a   Sheppard, S ^a   Pfent, C ^a   Safe, S ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Dog; Mammary carcinoma; Osteosarcoma; Tolfedine

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; RNA; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP; TUMOR PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; NEOPLASM; OSTEOSARCOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; NEOPLASMS; ORTHO-AMINOBENZOATES; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SP TRANSCRIPTION FACTORS; UP-REGULATION;

ANIMALIA; CANIS FAMILIARIS;

EID: 84864024106     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2012.00931.x     Document Type: Article

References (22)

1. Safe S, Abdelrahim M. Sp transcription factor family, and its role in cancer. Eur J Cancer 2005;41:2438-2448.
2. Wang L, Guan X, Gong W, et al. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis 2005;22:205-213.
3. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008;68:5345-5354.
4. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Drugs that target specificity proteins downregulate epidermal growth receptor in bladder cancer cells. Mol Cancer Res 2010;8:739-750.
5. Abdelrahim M, Baker CH, Safe S, et al. Regulation of vascular endothelial growth factor receptor-1 (VEGFR1) expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007;67:3286-3294.
6. Abdelrahim M, Smith R III, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression, and proliferation of pancreatic cancer cells. Cancer Res 2004;64:6740-6749.
7. Myllylä VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998;38:201-207.
8. Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl 1979;24:9-12.
9. Laven RA, Lawrence KE, Weston JF, et al. Assessment of the duration of the pain response associated with lameness in dairy cows, and the influence of treatment. N Z Vet J 2008;56:210-217.
10. Grandemange E, Fournel S, Boisramé B. Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. J Vet Pharmacol Ther 2007;30:503-507.
11. Lascelles BD, Court MH, Hardie EM, Robertson SA. Nonsteroidal anti-inflammatory drugs in cats: A review. Vet Anaesth Analg 2007;34:228-250.
12. Roze M, Thomas E, Davot JL. Tolfenamic acid in the control of ocular inflammation in the dog: Pharmacokinetics, and clinical results obtained in an experimental model. J Small Anim Pract 1996;37:371-375.
13. McKellar QA, Lees P. Gettinby G. Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships. Eur J Pharmacol 1994;253:191-200.
14. Vetoquinol Company. Tolfedine Package Insert. Compendium of Veterinary products.
15. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007;67:3286-3294.
16. Wolfe LG, Oliver JL, Smith BB, et al. Biologic characterization of canine melanoma cell lines. Am J Vet Res 1987;48:1642-1648.
17. Wolfe LG, Smith BB, Toivio-Kinnucan MA, et al. Biologic properties of cell lines derived from canine mammary carcinomas. J Natl Cancer Inst 1986;77:783-792.
18. Else RW, Norval M, and Neill WA. The characteristics of a canine mammary carcinoma cell line, REM 134. Br J Cancer 1982;46:675-681.
19. Vinothini G, Balachandran C, Nagini S. Evaluation of molecular markers in canine mammary tumors: Correlation with histological grading. Oncol Res 2009;18:193-201.
20. Bergman P. Canine oral melanoma. Clin Tech Small Anim Pract 2007;22:55-60.
21. Selvarajah G, Kirpensteign J. Prognostic and predictive biomarkers of canine osteosarcoma. Vet J 2010;185:28-35.
22. Chen R, Liliental JE, Kowalski PE, et al. Regulation of transcription of hypoxia-inducible factor-1α (HIF-1α) by heat shock factors HSF2, and HSF4. Oncogene 2011;30(22):2570-2580.